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Abstract
Background: Long noncoding RNAs (lncRNAs) play crucial roles in tumorigenesis, and lncRNA taurine-upregulated
gene 1 (TUG1) has been proven to be associated with several human cancers. However, the mechanisms of TUG1-
involved regulation remain largely unknown.
Methods: We examined the expressions of TUG1 in a cohort of 89 patients with non-small cell lung cancer (NSCLC)
to determine the association between TUG1 expression and clinical parameters. We used circular chromosome
conformation capture (4C) coupled with next-generation sequencing to explore the genome regions that interact
with TUG1 and the TUG1-mediated regulation.
Results: TUG1 was significantly downregulated, and the TUG1 downregulation correlated with sex (p = 0.006),
smoking status (p = 0.016), and tumor differentiation grade (p = 0.001). Knockdown of TUG1 significantly promoted
the proliferation of NSCLC cells. According to the bioinformatic analysis result of TUG1 4C sequencing data, 83
candidate genes and their interaction regions were identified. Among these candidate genes, CUGBP and Elav-like
family member 1 (CELF1) are potential targets of TUG1 in-trans regulation. To confirm the interaction between TUG1
and CELF1, relative expressions of CELF1 were examined in TUG1 knockdown H520 cells; results showed that CELF1
was significantly upregulated in TUG1 knockdown H520 cells. RNA immunoprecipitation was then performed to
examine whether TUG1 RNA was bound to PRC2, a TUG1-involved regulation mechanism reported in previous
studies. The results demonstrated that TUG1 RNA was bound to enhancer of zeste protein 2/embryonic ectoderm
development (EZH2/EED), which is essential for PRC2. Finally, our designed ChIP assay revealed that the EZH2/EED
was bound to the promotor region of CELF1 within 992 bp upstream of the transcript start site.
Conclusion: TUG1 is downregulated in NSCLC. Using TUG1 4C sequencing and bioinformatic analysis, we found
CELF1 to be a potential target of TUG1 RNA in in-trans regulation. Moreover, subsequent experiments showed that
TUG1 RNA could bind to PRC2 in the promotor region of CELF1 and negatively regulate CELF1 expressions in H520
cells. Our results may facilitate developing new treatment modalities targeting TUG1/PRC2/CELF1 interactions in
patients with NSCLC.
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Background
As a leading cause of cancer-related mortality world-
wide, lung cancer has been investigated in numerous
molecular genetic studies aimed at developing new treat-
ment strategies [1]. Lung cancer is classified into two
types according to biological characteristics: non-small
cell lung cancer (NSCLC) (accounting for approximately
85 % of cases), and small cell lung cancer (SCLC) [2].
The overall prognosis for lung cancer is poor; in 2004,
the overall 5-year survival rate at all stages was 16.8 %
[1]. Small molecule tyrosine kinase inhibitors targeting re-
ceptor tyrosine kinases (RTKs), such as epidermal growth
factor receptor (EGFR) and anaplastic lymphoma kinase
(ALK), play crucial roles in NSCLC treatment. Nonethe-
less, prognosis and outcomes for patients with certain
genetic features (e.g., EGFR mutations, K-Ras mutations,
and EML4-ALK rearrangement) remain poor [3].
Long noncoding RNAs (lncRNAs), defined as ncRNAs
with transcripts longer than 200 nucleotides, have a crit-
ical role in the development process, cellular homeosta-
sis, genomic imprinting, and pluripotency of embryonic
stem cells [4–6]. The importance of lncRNA regulation is
emphasized by their roles in the etiology human diseases
[7–9]. Several lncRNAs are involved in the carcinogenesis,
disease progression, or metastasis of human cancers (e.g.,
MALAT1 in hepatocellular carcinoma, colorectal carcin-
oma, bladder cancer, and lung cancer; HOTAIR in breast
cancer, hepatocellular carcinoma, pancreatic cancer, gas-
tric cancer, laryngeal cancer, and nasopharyngeal cancer;
H19 in cervical, gastric, bladder, breast, esophageal, and
lung cancer; PCGEM1 in prostate cancer) [10].
The lncRNA taurine-upregulated gene 1 (TUG1) is a
nonprotein-coding gene located on chromosome 22q12.2
that transcribes to a 6.7-kilobase-long, spliced, and polya-
denylated RNA. Upregulated by taurine in developing ret-
inal cells, TUG1 is essential for normal photoreceptor
development. Knockdown of TUG1 leads to malformed
outer segments of photoreceptors in newborn murine ret-
inas [11]. In human cancers, TUG1 has been reported to
be associated with urothelial carcinoma of the bladder,
osteosarcoma, esophageal squamous cell carcinoma, and
NSCLC [12–15]. Only a few studies have proposed the
mechanisms of TUG1 regulation [15, 16]. In the present
study, we examined TUG1 expression in NSCLC patients
to determine the association between TUG1 expressions
and clinical parameters. LncRNAs regulate protein-coding
gene expression through chromatin remodeling, transcrip-
tional modulation, and nuclear architecture/subnuclear
localization [17]. Chromosome conformation capture (3C)
techniques are methods for detecting the coassociation
between chromatins through the fixation of living cells,
which preserves the genomic architecture in its native
state before fragmentation by restriction enzyme diges-
tion, and the ligation of chromatin fragments that are in
physical proximity in the nuclear space [18]. Circular
chromosome conformation capture (4C), which involves
the circularization of chimeric DNA fragments and the
amplification of DNA sequences with primers within the
bait but proximal to the target sequence during ligation,
can be used to screen for interactions without perception
of the existence of two different complexes [19]. To fur-
ther investigate TUG1 regulation, we used the 4C method
to analyze genome-wide interactions with the TUG1 gene
and found a novel target of TUG1 regulation.
Methods
Patient samples
Tumor and nontumor tissue samples were obtained
from 89 patients with NSCLC. All participants provided
written informed consent. The study was approved by
the Institutional Review Board of Kaohsiung Medical
University Hospital (KMUH-IRB-980524). The baseline
characteristics of the patients with NSCLC (age, sex,
smoking status, Eastern Cooperative Oncology Group
performance status (ECOG PS), histology, differentiation
grade, and TNM stage) were collected from chart
records.
RNA extraction and qRT-PCR
Total RNA extraction, complementary DNA (cDNA)
generation, and polymerase chain reaction (PCR) were
performed according to manufacturer protocals. The de-
tailed procedures and primer sequences are listed in
Additional file 1. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control.
Cell culture and shRNA transfection
H520, H1299, and REH cells were cultured in RPMI
medium (GIBCO BRL, Gaithersburg, MD, USA) supple-
mented with 10 % fetal bovine serum (GIBCO BRL) at
37 °C in a 5 % CO2 atmosphere. TUG1 shRNA, scramble
RNA, and mock were obtained from the National
Research Program for Biopharmaceuticals and were trans-
fected into H520 and H1299 cells (400 ng TUG1 shRNA
added to 600 μL of cells, 2 × 105 cells/mL) by using
Lipofectamine 2000 (Life Technologies). Transfection effi-
ciency was determined through quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR).
Cell proliferation assay
Cell proliferation assay was used to examine whether
TUG1 knockdown affects the viability of NSCLC cells.
In brief, transfected H520 and H1299 cells were plated
in 96-well plates (2 × 105 cells/mL, 100 μL/well). After
48 h, cell proliferation and viability were examined
using the MTT assay. All experiments were performed
in triplicate.
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Circular chromosome conformation capture
The 4C experiment included the following basic proce-
dures: formaldehyde cross-linking, and digestion and
ligation of the known bait chromatin (i.e., TUG1 in this
study) and the unknown sequences. Circular chimeric
chromatin was then decross-linked, and the unknown
sequences were amplified with inverse PCR by using the
bait-specific primers. We followed the 4C method
described by Stadhouders et al. [18], which involved sec-
ondary digestion and ligation between decross-linked
and inverse PCR amplification. Secondary digestion is
advantageous because it decreases the size of the DNA
circles, enabling efficient PCR amplification of frag-
ments. Six-base-recognizing (six-cutter) enzymes, which
perform well on cross-linked chromatin, are generally
recommended for primary digestion; any four-cutter
enzyme that is insensitive to mammalian DNA methyla-
tion and has high religation efficiency can be used for
secondary digestion. In addition, the final combination
of primary and secondary restriction enzymes generates
a suitable bait fragment for designing bait-specific
primers for inverse PCR, depending on their compatibil-
ity [18]. Based on our bait gene sequence (TUG1), a six-
cutter enzyme (HindIII) was used as the primary
digestive enzyme, and a four-cutter enzyme (CviQI) that
can generate a bait sequence suitable for further primer
design in HindIII-digested TUG1 fragments was used as
the secondary digestive enzyme. In brief, REH cells were
cross-linked with 1 % formaldehyde for 10 min at room
temperature to preserve the three-dimensional nuclear
architecture. HindIII was used to digest cross-linked
chromatin (primary digestion). The digested chromatin
was then ligated using the T4 DNA ligase. The digested
and ligated chromatin was then decross-linked and sub-
mitted to the second restriction digestion by using CviQI
to reduce the size of the fragments. Inverse PCR reactions
were performed using TUG1-specific primers harboring
Illumina adapter sequences to amplify the genomic DNA
fragments ligated to TUG1 (first PCR: forward 5’-gtctccga-
tagtgcacacagc-3’, reverse 5’-gaccatctccttcaggacca-3’; nested
PCR: forward 5’-cattcagccaatcacaaagct-3’, reverse 5’-cagatt-
tatgacatagttccttccaa-3’).
Next-generation sequencing
The PCR products were purified using the Qiagen Mini-
Elute kit. After purification, the amplicon was prepared
for sequencing by using a Truseq DNA library prepar-
ation kit (Illumina). According to the TruSeq DNA Sam-
ple Preparation protocol, 100-ng purified amplicon pools
were repaired to generate blunt-ended, 5’-phosphory-
lated DNA, and an A-tailing reaction compatible with
the adapter ligation strategy was performed. The ligation
product was purified by sample purification beads. To
enrich the library, an enhanced PCR mix was used to
perform PCR amplification. The size distribution of the
library was verified using the High-Sensitivity DNA Kit
(Agilent), and the concentration of the library was quan-
tified using the GeneRead Library Quant Kit (Qiagen).
The library was diluted and sequenced with 500 paired-
end cycles on the Illumina MiSeq by following the standard
protocol.
Bioinformatic analysis of TUG1 4C-sequencing data
Removing known fragments from sequencing reads
Removal of known fragments from sequencing reads in-
volved three steps. First, forward and reverse sequencing
reads were merged into one sequence when the length
of the overlapping region between the forward and
reverse sequencing reads was more than 20 nt. Second,
BLAST, a widely used bioinformatic software of se-
quence searching, was used to identify the location of
the known fragments and primers [20]. The known frag-
ments were located in the regions between the primers
and the cutting site of the enzymes. The alignment simi-
larity for BLAST was set at 95 %. Finally, results from
Blast showed the location of known fragments and
primers. These primers and known fragments of sequen-
cing reads were removed from the sequencing reads.
The remaining region of the sequencing reads was
labeled “unknown fragments.”
Identifying potential TUG1 interaction regions
The Bowtie2 software is an efficient tool for aligning se-
quencing reads against reference sequences [21]. Bow-
tie2 was used to align unknown fragments against
human genome sequences (Grch38.p2 was used in the
present study). Subsequently, fourSig, a software suite
for analyzing and visualizing 4C-seq data, was used to
identify the potential TUG1 interactive regions [22]. The
command “bamToReTab.pl –H 210 500 300 bow-
tie2_output hind3_site.txt nla3_site.txt NONE > foursi-
g_output” was used to obtain the primary results from
fourSig. The primary results were then used to scan for
potential interaction regions. The window size was set at
50 (i.e., 50 fragments in the window). After scanning for
the interaction regions, fourSig provided three categories
of regions, which were defined as potential TUG1 inter-
action regions. The regions and their associated genes
were listed and then annotated according to the genomic
location of known human genes. These TUG1 inter-
active regions, having over 100 reads of coverage, were
used as TUG1 interaction region candidates.
RNA immunoprecipitation (RIP)
RNA immunoprecipitation (RIP) assays were performed
using ChIP-IT (Active Motif, Carlsbad, CA, USA), ac-
cording to the Active Motif protocol. Anti-EED (Aviva
Systems Biology, San Diego, CA, USA), anti-EZH2 (Cell
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Signaling Technology, Danvers, MA, USA) antibodies,
and IgG were used. The detailed procedures are listed in
Additional file 2.
DNA ChIP
DNA ChIP assays were performed using ChIP-IT (Active
Motif, Carlsbad, CA, USA), according to manufacturer in-
structions. Anti-EED (Aviva Systems Biology, San Diego,
CA, USA), anti-EZH2 (Cell Signaling Technology, Danvers,
MA, USA) antibodies, and IgG were used. The detailed
procedures are listed in Additional file 2. Six sets of primers
were designed to amplify the CELF1 promotor region. The
primer sequences are listed in Additional file 3: Table S1.
Statistical analysis
The differences in RNA expression between tumor and
nontumor tissues from NSCLC patients were analyzed
using a paired t test. The association between relative
TUG1 RNA expression levels and clinical parameters
(age, sex, smoking status, ECOG PS, histology, differen-
tiation grade, and TNM stage) was analyzed using a t
test and ANOVA. TUG1 shRNA and scramble shRNA
transfected cells in the MTT assay were compared and
analyzed through an independent samples t test. Statis-
tical analyses were performed using SAS version 9.3;
p < 0.05 was considered statistically significant.
Results
TUG1 is downregulated in NSCLC tissues and affects
NSCLC cell prolifiration
We determined the levels of TUG1 expression in 89
pairs of NSCLC tumor and nontumor lung tissues by
using qRT-PCR. TUG1 was significantly downregulated
in the cancerous tissues compared with the normal
counterparts (p < 0.01) (Fig. 1a). Over 50 % reduction in
TUG1 expression was observed in 60 % (35/58) of the
TUG1-downregulated NSCLC tissues (Fig. 1b). More-
over, TUG1 downregulation correlated significantly with
sex (p = 0.006), smoking status (p = 0.016), and tumor
differentiation grade (p = 0.001) (Fig. 1c–e). Correlations
with the other parameters (i.e., histology, age (<65
and ≥65 years), and TNM stage) were nonsignificant
(Additional file 4: Table S2). No differences were ob-
served in the survival rates between patients with TUG1
Fig. 1 TUG1 expressions in NSCLC lung tissues. a TUG1 was examined in 89 pairs of NSCLC tumor and nontumor tissues through qRT-PCR.
Fold changes in TUG1 expression were demonstrated, revealing significant downregulation of TUG1 in tumor tissues. b Log2 fold changes in
TUG1 expressions (T/N) of each case are plotted. c–e TUG1 expression levels were significantly lower in male patients, smokers, and those with
poor-differentiation tumors (*p < 0.05, **p < 0.01). f Survival curves for patients with TUG1 downregulation (n = 58) and TUG1 upregulation (n = 31)
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downregulation and those with TUG1 upregulation until
60 months after diagnosis, indicating that survival is lower
among TUG1-downregulated patients compared with
TUG1-upregulated patients (Fig 1f). To explore the effects
of TUG1 regulation on cell proliferation, TUG1 knock-
down was performed using shRNAs transfection in H520
and H1299 cells. The knockdown efficiencies were vali-
dated through qRT-PCR (Fig. 2a and b). The MTT assay
showed that the TUG1 knockdown increased the cell
proliferation in the H520 and H1299 cells (Fig. 2c and d).
CELF1 is a potential target of TUG1 interaction and could
be negatively regulated by TUG1 RNA
LncRNAs have been shown to regulate their target genes
by physically connecting their genomic locus with the
genomic regions of the target genes [23]. To further inves-
tigate TUG1-involved regulation, we applied 4C coupled
with next-generation sequencing procedures to identify
the TUG1 interaction regions. The 4C experiment is a 3C-
based technique. 3C-based techniques have been applied in
investigating lncRNA regulation mechanisms. Using high-
throughput chromosome conformation capture, Wang
et al. reported the necessity of induced proximity between
the genomic region of HOTTIP and WDR5 in HOTTIP
RNA regulation of its target genes [24]. Agarose gel electro-
phoresis of formaldehyde cross-linked, restriction-enzyme-
digested chromatin DNA, and PCR products amplified
using TUG1-specific primers are illustrated in Additional
file 5: Figure S1. The TUG1 4C-sequencing data had
6,302,180 paired-end sequencing reads. The data were
deposited in NCBI SRA, project number: PRJNA293783.
Figure 3 shows the analysis flowchart of the TUG1 data.
According to the analysis results, 83 candidate genes were
identified. These genes and their interaction regions are
listed in Additional file 6: Tables S3 and S4. The TUG1
interaction map within these candidate genes is shown in
Fig. 2 Knockdown of TUG1 increases cell proliferation in NSCLC cells. NSCLC cells were transfected with shRNA A2 and B2 for the TUG1 knockdown,
and scramble RNA was used as the control. The efficiencies of the TUG1 knockdown were assessed through real-time qRT-PCR in three independent
experiments. a and (b) shRNA A2 and B2 demonstrated effective knockdown efficacy in H520 and H1299 cells. c and (d) Cell viabilities were examined
in shRNA A2 and B2 knockdown H520 and H1299 cells. Significantly increased cell viabilities were noted compared with the scramble RNA in the three
independent experiments (*p < 0.05)
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Fig. 4a. Every candidate interaction region was examined to
determine whether Hind III and CviQI digest sites were
close to the 5’ and 3’ end of the region (Additional file 6:
Table S5). Among the remaining candidate genes, the
protein-coding gene CELF1 had one of the highest abun-
dances. Because the other protein coding gene, MORC2,
was located in the same chromosome as TUG1, the possi-
bility of self-ligation cannot be excluded. Moreover,
previous studies have reported that TUG1 regulation is
involved in in-trans regulation. Therefore, an additional ex-
periment was performed on CELF1 to confirm the inter-
action between TUG1 and CELF1. The interaction region
of CELF1 located at chr11:47496189–47496438, and the
read distribution of CELF1 are illustrated in Fig. 4b. The
levels of CELF1 expression were detected using qRT-PCR
in the TUG1 knockdown H520 cells. CELF1 was found to
Fig. 3 Analysis flowchart for the TUG1 4C-sequencing data
Fig. 4 TUG1 interaction map and read distribution of the TUG1 interaction region (CELF1). a Circos plots depicting transinteractions and a compact
representation of the interactions with other chromosomes. b The interaction region of CELF1 was located at chr11:47496189-47496438. HindIII and
CviQI digest sites were located at chr11: 47496402 and chr11: 47496402, respectively
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be significantly upregulated in these cells (p < 0.05, Fig. 5a).
Because lncRNAs might be involved in the gene regulatory
network by guiding chromatin-modifying complexes to
their sites of action, some lncRNAs may be central to the
epigenetic control of gene expression [25]. TUG1 was pre-
viously shown to bind to PRC2 and epigenetically repress
the expression of genes involved in cell-cycle regulation
[26]. Yang et al. reported that TUG1 represses E2F-
regulated growth-control genes (MCM3, PCNA, and
MSH2) by relocating them to polycomb bodies [16]. Zhang
et al. screened the HOX family in TUG1 knockdown
NSCLC cells, finding that TUG1 can negatively regulate
HOX7 by binding to PRC2 [15]. Therefore, we investigated
whether PRC2 is involved in the regulation of TUG1 on
CELF1. We used the RIP assay to examine the association
of PRC2 and TUG1 RNA. The binding of TUG1 RNA and
enhancer of zeste protein 2/embryonic ectoderm develop-
ment (EZH2/EED), which is crucial for PRC2, was validated
in the RIP assay (Fig. 5b). Furthermore, we designed six sets
of primers for the promotor region of CELF1 and found
that EZH2/EED was bound to the sequences within 992 bp
upstream of the transcript start site (Fig. 5c). The spatial
proximity of TUG1 and CELF1 chromatin segments was
revealed through TUG1 4C-sequencing and bioinformatic
analysis. The interaction between TUG1 RNA and CELF1
was confirmed by the negative regulation of TUG1 RNA
on CELF1 and the occupancy of TUG1 RNA/PRC2 in the
promoter region of CELF1.
Discussion
TUG1 was first identified as a noncoding RNA upregu-
lated by taurine in developing retinal cells. Several genes
related to cell-death pathways (AIF, Alix/AIP1, NIP3,
and NAPOR) were shown to be upregulated in TUG1
knockdown cells and apoptosis was found to increase,
suggesting that TUG1 is involved in cell survival [11].
Studies on human cancers have concluded that TUG1 is
overexpressed in urothelial carcinoma of the bladder
and is associated with high-grade and advanced-stage
diseases. Inhibition of cell proliferation and induction of
apoptosis were observed in TUG1 knockdown bladder
urothelial carcinoma T24 and 5637 cells [12]. Similar
results have been noted in osteosarcoma and esophageal
squamous cell carcinomas [13, 14]. In lung cancer,
TUG1 was shown to be downregulated in NSCLC, and
TUG1 expression was shown to be significantly lower in
advanced-stage diseases and larger tumors [15]. In our
NSCLC cohort, TUG1 was downregulated in lung cancer
tissues compared with the nontumor tissues. In addition,
TUG1 levels were significanly lower in the patients who
were male, smokers, or had poorly differentiated tumors.
No significant difference in TUG1 levels was observed
Fig. 5 Validation of interactions between CELF1 and TUG1. a Relative expressions of CELF1 in the mock, shRNA-A2, or shRNA-B2 transfected H520
cells were detected through qRT-PCR in three independent experiments. Significant CELF1 upregulation was noted in the TUG1 knockdown H520
cells. (*p < 0.05) (b) RIP experiments were performed on H520 cells by using EED, EZH2, and IgG. Coprecipitated RNA was tested through qRT-PCR
for TUG1. c Six primer sets were designed for ChIP experiments on EZH2 and EED of the promotor regions of CELF1. qPCR was used to determine
the quantitation of ChIP assays. Representative images of the three independent experiments are shown
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among patients with different disease stages; this could
be attributed to the limited numbers of patients with
advanced-stage disease in this study (four patients with
stage IV disease).
LncRNAs have been described in the processes of gene
silencing, imprinting, and gene activation [8]. In our
study, CELF1 was identified through a 4C-sequencing
approach; the TUG1-involved regulation of CELF1 was
confirmed through MTT assay, RIP, and DNA ChIP
experiments. The 4C techniques, which are based on 3C
techniques, enable identifying physical interactions between
chromatin segments [27, 28]. In addition to 3C procedures,
4C procedures also involve a second restrictive enzyme re-
action; 4C procedures introduce a circularization step after
the reversal of the cross-linking, increase the likelihood of
promoting intermolecular ligation events, and generate
high-resolution interaction maps [29]. Previous research re-
vealed a strong connection between the spatial organization
of chromatin and gene regulation, particularly the
promotor-enhancer contacts induced by chromatin looping
[30]. Kaufmann et al. conducted a large-scale investigation
of the interchromosomal segment and gene contact net-
works, and showed that coexpression and functional simi-
larity correlate with spatial proximity [31]. In the present
study, we applied 4C procedures followed by next-
generation sequencing (NGS) and bioinformatic analysis to
investigate the possible interactions of TUG1 with other
elements in the genome and found this approach effective
for identifying lncRNA regulation targets.
CELF1 belongs to the CELF family (CUG-BP, Elav-like
family). First recognized in human cells as a nuclear RNA-
binding protein, CELF1 is expressed broadly in human
tissues, such as the heart, skeletal muscles, and brain [32].
It is expressed in both the nucleus and cytoplasm, and is
involved in pre-mRNA alternative splicing, RNA editing
in the nucleus, and deadenylation, RNA decay, and trans-
lation in the cytoplasm [32]. CELF1 was shown to interact
with the 5’-region of c/ebpβmRNA, and it is associated
with polysomes that translate low molecular weight
isoforms of C/EBPβ [33]. In chronic myeloid leukemia,
CELF1 is repressed, resulting in a decrease of C/EBPβ iso-
forms, particularly LAP2. Imatinib (STI571) treatment can
reinduce C/EBPβ expression that appears to depend on
CELF1 expression and the integrity of the CUG-rich inter-
cistronic region of c/ebpβmRNA [34]. In oral squamous
cancer cells, CELF1 is overexpressed, and CELF1 depletion
reduces proliferation and increases apoptosis in these cells
[35]. Wu et al. reported CELF1 overexpression in NSCLC
and that siRNA-mediated silencing of CELF1 markedly
reduced the survival rate and colony formation of lung
cancer cells [36]. Although the roles of CELF1 in embry-
onic development and carcinogenesis were revealed, the
upstream regulation of CELF1 has been overlooked. Our
results reveal that CELF1 is negatively regulated by TUG1
in NSCLC cells. Microarray in TUG1 knockdown murine
retinal cells showed upregulation of the other members of
the same CELF subfamily, CELF2 (NAPOR) [11]. CELF1
and CELF2 exhibit conserved, partially overlapping,
developmental-stage, tissue-specific expression [37]. In
murine eyes, CELF1 protein expression is higher in the
lens, whereas CELF2 protein is more highly expressed in
the retinae [37]. This may explain why Young et al. found
no linkage between TUG1 and CELF1—because that study
focused on murine retinal cells. Therefore, CELF1 and
CELF2 may share similar regulatory control mechanisms in
a tissue-specific pattern through TUG1/PRC2 interaction.
Conclusion
LncRNA TUG1 is downregulated in NSCLC. We found
that this downregulation is associated with sex, smoking
status, and the differentiation grade of patients with
NSCLC. Our study demonstrates a novel target of TUG1
and validates the interactions of TUG1/PRC2/CELF1 in
NSCLC cells. The application of 4C techniques enabled a
genome-wide search for lncRNA targets, the findings of
which may facilitate future studies of lncRNAs. Our
results may be used in the development of new treatment
modalities targeting TUG1/PRC2/CELF1 interactions in
patients with NSCLC.
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